Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia.
Researchers from the National University of Singapore have identified new biomarkers related to the cognitive impairment associated with cancer known as chemobrain.
In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide.
Researchers have defined the roles of various cells in the bone marrow that are thought to control the fate of the nearly half million blood cells that develop there each day.
Many people fighting a very aggressive form of acute myeloid leukemia (AML) don't survive more than five years. These very sick patients are often unable to receive the only cure -- a bone marrow transplant. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell's internal machinery, where they may have found a key to treating the aggressive blood cancer.
An advance in the cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings.
In Marfan Syndrome (MFS), aortic dilatation is one of the main cardiovascular manifestations which deteriorate due to the physiological changes during pregnancy. We aimed to assess the up-to-date management and outcomes of aortic root dilation and dissection (AoD) in pregnancy with MFS
This recommendation from the US Preventive Services Task Force (USPSTF) updates its 2006 statement regarding screening for elevated blood lead levels in children and pregnant women.
Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in animals may set the stage for a new therapy for a subset of patients with hemophilia who now develop antibodies to the standard maintenance treatment and then require on-demand 'bypass' therapy.